Ewha Med J.  2024 Jan;47(1):e11. 10.12771/emj.2024.e11.

The Sex and Gender Equity in Research (SAGER) guidelines: implementation and checklist development: a Korean translation

• Epps HV
• Astudillo O
• Martín YDP
• Marsh J

• KMID: 2553292
• DOI: http://doi.org/10.12771/emj.2024.e11

Figure

• 

  그림 1. The Lancet Rheumatology에 출판된 논문의 SAGER(Sex and Gender Equity in Research) 지침 준수 비율. 시범 프로그램 개시 전인 2021년 1월~5월, 개시 후인 2021년 6월~2022년 8월에 출판된 논문 중 성별/젠더 데이터를 초록에 보고한 비율, 인구사회적 특성 표에 구분하여 제시한 비율, 이상 반응 분석에 성별/젠더에 따른 세분화 자료를 제시한 비율, 그리고 자료분석에 성별/젠더를 적용한 비율.

Reference

References

1. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature. 2014; 509(7500):282–283. DOI: 10.1038/509282a. PMID: 24834516. PMCID: PMC5101948.

2. Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007; 55(2):81–95. DOI: 10.1016/j.phrs.2006.11.001. PMID: 17129734.

3. Legato MJ, Johnson PA, Manson JE. Consideration of sex differences in medicine to improve health care and patient outcomes. J Am Med Assoc. 2016; 316(18):1865–1866. DOI: 10.1001/jama.2016.13995. PMID: 27802499.

4. Wagner AD, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C, et al. Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol. 2019; 30(12):1914–1924. DOI: 10.1093/annonc/mdz414. PMID: 31613312.

5. Heidari S, Babor TF, Castro PD, Tort S, Curno M. Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev. 2016; 1:2. DOI: 10.1186/s41073-016-0007-6. PMID: 29451543. PMCID: PMC5793986.

6. Mauvais-Jarvis F, Merz NB, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020; 396(10250):565–582. DOI: 10.1016/S0140-6736(20)31561-0. PMID: 32828189.

7. Perez CC. Invisible women: exposing data bias in a world designed for men. London: Chatto & Windus;2019.

8. National Institutes of Health [NIH]. NIH policy on sex as a biological variable [Internet]. Bethesda (MD): NIH;c2022. [cited 2022 May 23]. Available from: https://orwh.od.nih.gov/sex-gender/orwh-mission-area-sex-gender-in-research/nih-policy-on-sex-as-biological-variable#:~:text=NIH%20expects%20that%20sex%20as.

9. National Institutes of Health [NIH]. 2019–2023 trans-NIH strategic plan for women’s health research [Internet]. Bethesda (MD): NIH;c2018. [cited 2022 May 23]. Available from: https://orwh.od.nih.gov/about/trans-nih-strategic-plan-womens-health-research.

10. U.S. Food and Drug Administration. Enhancing the diversity of clinical trial populations: eligibility criteria, enrollment practices, and trial designs guidance for industry [Internet]. Silver Spring (MD): U.S. Food and Drug Administration;c2020. [cited 2022 May 23]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial.

11. Rubin E. Striving for diversity in research studies. N Engl J Med. 2021; 385(15):1429–1430. DOI: 10.1056/NEJMe2114651. PMID: 34516052.

12. U.S. Food and Drug Administration. Drug trials snapshots [Internet]. Silver Spring (MD): U.S. Food and Drug Administration;c2022. [cited 2022 May 23]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots.

13. Peters SAE, Babor TF, Norton RN, Clayton JA, Ovseiko PV, Tannenbaum C, et al. Fifth anniversary of the sex and gender equity in research (SAGER) guidelines: taking stock and looking ahead. BMJ Glob Health. 2021; 6(11):e007853. DOI: 10.1136/bmjgh-2021-007853. PMID: 34815246. PMCID: PMC8611433.

14. Elsevier. Inclusion and diversity [Internet]. Amsterdam (NL): Elsevier;c2022. [cited 2022 May 23]. Available from: https://www.elsevier.com/about/inclusion-diversity-and-equity.

15. Springer. Sex and gender in research (SAGER guidelines) [Internet]. Cham (CH): Springer;c2022. [cited 2022 May 23]. Available from: https://www.springer.com/gp/editorial-policies/sex-and-gender-in-research-sager-guidelines.

16. International Committee of Medical Journal Editors [ICMJE]. Preparing a manuscript for submission to a medical journal [Internet]. Philadelphia (PA): ICMJE;c2022. [cited 2022 May 23]. Available from: https://www.icmje.org/recommendations/browse/manuscript-preparation/preparing-for-submission.html#two.

17. The Lancet Rheumatology. Getting serious about sex and gender. Lancet Rheumatol. 2021; 3(5):E313. DOI: 10.1016/S2665-9913(21)00118-1. PMID: 38279386.

18. Tang C, Hamad N. Trials and tribulations: including women in cancer clinical research. Lancet Haematol. 2021; 8(7):E477–E478. DOI: 10.1016/S2352-3026(21)00165-4. PMID: 34171277.

19. Moher D, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Br Med J. 2010; 340:c869. DOI: 10.1136/bmj.c869. PMID: 20332511. PMCID: PMC2844943.

20. Sweet DJ. New at cell press: the inclusion and diversity statement. Cell. 2021; 184(1):1–2. DOI: 10.1016/j.cell.2020.12.019. PMID: 33417857.

21. Robbins R. AI systems are worse at diagnosing disease when training data is skewed by sex [Internet]. Boston (MA): STAT;c2020. [cited 2022 May 23]. Available from: https://www.statnews.com/2020/05/25/ai-systems-training-data-sex-bias/.

22. Ledford H. Millions of black people affected by racial bias in health-care algorithms. Nature. 2019; 574(7780):608–609. DOI: 10.1038/d41586-019-03228-6. PMID: 31664201.

23. Hunt L, Schiebinger L. Sex, gender, and diversity analysis in research policies of major public granting agencies: a global review [Internet]. Charlottesville (VA): OSF Preprints;c2021. [cited 2022 May 23]. Available from: https://osf.io/preprints/osf/3agxf.

24. Schiebinger L, Leopold SS, Miller VM. Editorial policies for sex and gender analysis. Lancet. 2016; 388(10062):2841–2842. DOI: 10.1016/S0140-6736(16)32392-3. PMID: 27979394.